메뉴 건너뛰기




Volumn 52, Issue 2, 2015, Pages 126-137

Novel Targeted Therapies in Diffuse Large B-Cell Lymphoma

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE RECEPTOR; BORTEZOMIB; BROMODOMAIN AND EXTRA TERMINAL PROTEIN; BRUTON TYROSINE KINASE INHIBITOR; CYCLOPHOSPHAMIDE; DOXORUBICIN; ENZASTAURIN; FOSTAMATINIB; IBRUTINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; PACRITINIB; PHOSPHATIDYLINOSITOL 3 KINASE; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE C BETA; PROTEIN KINASE SYK INHIBITOR; REGULATOR PROTEIN; RITUXIMAB; RUXOLITINIB; STAT PROTEIN; TRANSCRIPTION FACTOR EZH2; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENETOCLAX; VINCRISTINE; LYMPHOCYTE ANTIGEN RECEPTOR;

EID: 84925260858     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2015.01.007     Document Type: Review
Times cited : (23)

References (108)
  • 2
    • 1842413105 scopus 로고    scopus 로고
    • The Non-Hodgkin's Lymphoma Classification Project
    • A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma
    • The Non-Hodgkin's Lymphoma Classification Project. Blood 1997, 89(11):3909-3918. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma.
    • (1997) Blood , vol.89 , Issue.11 , pp. 3909-3918
  • 3
    • 24644500086 scopus 로고    scopus 로고
    • Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia
    • Sehn L.H., Donaldson J., Chhanabhai M., et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005, 23(22):5027-5033.
    • (2005) J Clin Oncol , vol.23 , Issue.22 , pp. 5027-5033
    • Sehn, L.H.1    Donaldson, J.2    Chhanabhai, M.3
  • 4
    • 77957965500 scopus 로고    scopus 로고
    • Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era
    • Gisselbrecht C., Glass B., Mounier N., et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin OncolJ Clin Oncol 2010, 28(27):4184-4190.
    • (2010) J Clin OncolJ Clin Oncol , vol.28 , Issue.27 , pp. 4184-4190
    • Gisselbrecht, C.1    Glass, B.2    Mounier, N.3
  • 5
    • 0028790440 scopus 로고
    • Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin[U+05F3]s lymphoma
    • Philip T., Guglielmi C., Hagenbeek A., et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin[U+05F3]s lymphoma. N Engl J Med 1995, 333(23):1540-1545.
    • (1995) N Engl J Med , vol.333 , Issue.23 , pp. 1540-1545
    • Philip, T.1    Guglielmi, C.2    Hagenbeek, A.3
  • 6
    • 77951638691 scopus 로고    scopus 로고
    • Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma
    • Moskowitz C.H., Schoder H., Teruya-Feldstein J., et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. J Clin OncolJ Clin Oncol 2010, 28(11):1896-1903.
    • (2010) J Clin OncolJ Clin Oncol , vol.28 , Issue.11 , pp. 1896-1903
    • Moskowitz, C.H.1    Schoder, H.2    Teruya-Feldstein, J.3
  • 7
    • 33847361987 scopus 로고    scopus 로고
    • The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP
    • Sehn L.H., Berry B., Chhanabhai M., et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007, 109(5):1857-1861.
    • (2007) Blood , vol.109 , Issue.5 , pp. 1857-1861
    • Sehn, L.H.1    Berry, B.2    Chhanabhai, M.3
  • 8
    • 0027444652 scopus 로고
    • The International Non-Hodgkin's Lymphoma Prognostic Factors Project
    • A predictive model for aggressive non-Hodgkin's lymphoma
    • The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993, 329(14):987-994. A predictive model for aggressive non-Hodgkin's lymphoma.
    • (1993) N Engl J Med , vol.329 , Issue.14 , pp. 987-994
  • 9
    • 0037142053 scopus 로고    scopus 로고
    • The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
    • Rosenwald A., Wright G., Chan W.C., et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346(25):1937-1947.
    • (2002) N Engl J Med , vol.346 , Issue.25 , pp. 1937-1947
    • Rosenwald, A.1    Wright, G.2    Chan, W.C.3
  • 10
    • 0034598746 scopus 로고    scopus 로고
    • Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
    • Alizadeh A.A., Eisen M.B., Davis R.E., et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403(6769):503-511.
    • (2000) Nature , vol.403 , Issue.6769 , pp. 503-511
    • Alizadeh, A.A.1    Eisen, M.B.2    Davis, R.E.3
  • 11
    • 57149089307 scopus 로고    scopus 로고
    • Stromal gene signatures in large-B-cell lymphomas
    • Lenz G., Wright G., Dave S.S., et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359(22):2313-2323.
    • (2008) N Engl J Med , vol.359 , Issue.22 , pp. 2313-2323
    • Lenz, G.1    Wright, G.2    Dave, S.S.3
  • 12
    • 10744228934 scopus 로고    scopus 로고
    • The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma
    • Savage K.J., Monti S., Kutok J.L., et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003, 102(12):3871-3879.
    • (2003) Blood , vol.102 , Issue.12 , pp. 3871-3879
    • Savage, K.J.1    Monti, S.2    Kutok, J.L.3
  • 13
    • 0043192901 scopus 로고    scopus 로고
    • A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma
    • Wright G., Tan B., Rosenwald A., Hurt E.H., Wiestner A., Staudt L.M. A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma. Proc Natl Acad Sci U S A 2003, 100(17):9991-9996.
    • (2003) Proc Natl Acad Sci U S A , vol.100 , Issue.17 , pp. 9991-9996
    • Wright, G.1    Tan, B.2    Rosenwald, A.3    Hurt, E.H.4    Wiestner, A.5    Staudt, L.M.6
  • 14
    • 84912072610 scopus 로고    scopus 로고
    • Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma
    • Roschewski M., Dunleavy K., Wilson W.H. Moving beyond rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone for diffuse large B-cell lymphoma. Leuk Lymphoma 2014, 55(11):2428-2437.
    • (2014) Leuk Lymphoma , vol.55 , Issue.11 , pp. 2428-2437
    • Roschewski, M.1    Dunleavy, K.2    Wilson, W.H.3
  • 15
    • 84885183435 scopus 로고    scopus 로고
    • Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma
    • Puvvada S., Kendrick S., Rimsza L. Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma. Cancer Genet 2013, 206(7-8):257-265.
    • (2013) Cancer Genet , vol.206 , Issue.7-8 , pp. 257-265
    • Puvvada, S.1    Kendrick, S.2    Rimsza, L.3
  • 16
    • 84871578597 scopus 로고    scopus 로고
    • Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?
    • Barton S., Hawkes E.A., Wotherspoon A., Cunningham D. Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?. Oncologist 2012, 17(12):1562-1573.
    • (2012) Oncologist , vol.17 , Issue.12 , pp. 1562-1573
    • Barton, S.1    Hawkes, E.A.2    Wotherspoon, A.3    Cunningham, D.4
  • 17
    • 84896403797 scopus 로고    scopus 로고
    • Accelerated therapeutic progress in diffuse large B cell lymphoma
    • Cai Q., Westin J., Fu K., et al. Accelerated therapeutic progress in diffuse large B cell lymphoma. Ann Hematol 2014, 93(4):541-556.
    • (2014) Ann Hematol , vol.93 , Issue.4 , pp. 541-556
    • Cai, Q.1    Westin, J.2    Fu, K.3
  • 18
    • 84891001835 scopus 로고    scopus 로고
    • Diffuse large B-cell lymphoma-treatment approaches in the molecular era
    • Roschewski M., Staudt L.M., Wilson W.H. Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol 2014, 11(1):12-23.
    • (2014) Nat Rev Clin Oncol , vol.11 , Issue.1 , pp. 12-23
    • Roschewski, M.1    Staudt, L.M.2    Wilson, W.H.3
  • 19
    • 66649127621 scopus 로고    scopus 로고
    • Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma
    • Compagno M., Lim W.K., Grunn A., et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature 2009, 459(7247):717-721.
    • (2009) Nature , vol.459 , Issue.7247 , pp. 717-721
    • Compagno, M.1    Lim, W.K.2    Grunn, A.3
  • 20
    • 0035905313 scopus 로고    scopus 로고
    • Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells
    • Davis R.E., Brown K.D., Siebenlist U., Staudt L.M. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med 2001, 194(12):1861-1874.
    • (2001) J Exp Med , vol.194 , Issue.12 , pp. 1861-1874
    • Davis, R.E.1    Brown, K.D.2    Siebenlist, U.3    Staudt, L.M.4
  • 21
    • 75749124332 scopus 로고    scopus 로고
    • Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin
    • Morin R.D., Johnson N.A., Severson T.M., et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 2010, 42(2):181-185.
    • (2010) Nat Genet , vol.42 , Issue.2 , pp. 181-185
    • Morin, R.D.1    Johnson, N.A.2    Severson, T.M.3
  • 22
    • 80052029516 scopus 로고    scopus 로고
    • Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
    • Morin R.D., Mendez-Lago M., Mungall A.J., et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature 2011, 476(7360):298-303.
    • (2011) Nature , vol.476 , Issue.7360 , pp. 298-303
    • Morin, R.D.1    Mendez-Lago, M.2    Mungall, A.J.3
  • 23
    • 79952430906 scopus 로고    scopus 로고
    • Inactivating mutations of acetyltransferase genes in B-cell lymphoma
    • Pasqualucci L., Dominguez-Sola D., Chiarenza A., et al. Inactivating mutations of acetyltransferase genes in B-cell lymphoma. Nature 2011, 471(7337):189-195.
    • (2011) Nature , vol.471 , Issue.7337 , pp. 189-195
    • Pasqualucci, L.1    Dominguez-Sola, D.2    Chiarenza, A.3
  • 24
    • 3042594986 scopus 로고    scopus 로고
    • BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma
    • Iqbal J., Sanger W.G., Horsman D.E., et al. BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma. Am J Pathol 2004, 165(1):159-166.
    • (2004) Am J Pathol , vol.165 , Issue.1 , pp. 159-166
    • Iqbal, J.1    Sanger, W.G.2    Horsman, D.E.3
  • 25
    • 73849145729 scopus 로고    scopus 로고
    • Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
    • Davis R.E., Ngo V.N., Lenz G., et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature 2010, 463(7277):88-92.
    • (2010) Nature , vol.463 , Issue.7277 , pp. 88-92
    • Davis, R.E.1    Ngo, V.N.2    Lenz, G.3
  • 26
    • 70350304558 scopus 로고    scopus 로고
    • PI3 kinase signals BCR-dependent mature B cell survival
    • Srinivasan L., Sasaki Y., Calado D.P., et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell 2009, 139(3):573-586.
    • (2009) Cell , vol.139 , Issue.3 , pp. 573-586
    • Srinivasan, L.1    Sasaki, Y.2    Calado, D.P.3
  • 27
    • 43549097394 scopus 로고    scopus 로고
    • Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma
    • Lam L.T., Wright G., Davis R.E., et al. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma. Blood 2008, 111(7):3701-3713.
    • (2008) Blood , vol.111 , Issue.7 , pp. 3701-3713
    • Lam, L.T.1    Wright, G.2    Davis, R.E.3
  • 28
    • 84878969076 scopus 로고    scopus 로고
    • SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas
    • Chen L., Monti S., Juszczynski P., et al. SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. Cancer Cell 2013, 23(6):826-838.
    • (2013) Cancer Cell , vol.23 , Issue.6 , pp. 826-838
    • Chen, L.1    Monti, S.2    Juszczynski, P.3
  • 29
    • 83455225523 scopus 로고    scopus 로고
    • SYK inhibition and response prediction in diffuse large B-cell lymphoma
    • Cheng S., Coffey G., Zhang X.H., et al. SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood 2011, 118(24):6342-6352.
    • (2011) Blood , vol.118 , Issue.24 , pp. 6342-6352
    • Cheng, S.1    Coffey, G.2    Zhang, X.H.3
  • 30
    • 77951002653 scopus 로고    scopus 로고
    • Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
    • Friedberg J.W., Sharman J., Sweetenham J., et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood 2010, 115(13):2578-2585.
    • (2010) Blood , vol.115 , Issue.13 , pp. 2578-2585
    • Friedberg, J.W.1    Sharman, J.2    Sweetenham, J.3
  • 31
    • 38049084406 scopus 로고    scopus 로고
    • Discovery of selective irreversible inhibitors for Bruton[U+05F3]s tyrosine kinase
    • Pan Z., Scheerens H., Li S.J., et al. Discovery of selective irreversible inhibitors for Bruton[U+05F3]s tyrosine kinase. Chem Med Chem 2007, 2(1):58-61.
    • (2007) Chem Med Chem , vol.2 , Issue.1 , pp. 58-61
    • Pan, Z.1    Scheerens, H.2    Li, S.J.3
  • 32
  • 33
    • 84886386342 scopus 로고    scopus 로고
    • Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas
    • Aalipour A., Advani R.H. Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas. Br J Haematol 2013, 163(4):436-443.
    • (2013) Br J Haematol , vol.163 , Issue.4 , pp. 436-443
    • Aalipour, A.1    Advani, R.H.2
  • 34
    • 77955625479 scopus 로고    scopus 로고
    • The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
    • Honigberg L.A., Smith A.M., Sirisawad M., et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 2010, 107(29):13075-13080.
    • (2010) Proc Natl Acad Sci U S A , vol.107 , Issue.29 , pp. 13075-13080
    • Honigberg, L.A.1    Smith, A.M.2    Sirisawad, M.3
  • 35
    • 84871806385 scopus 로고    scopus 로고
    • Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies
    • Advani R.H., Buggy J.J., Sharman J.P., et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013, 31(1):88-94.
    • (2013) J Clin Oncol , vol.31 , Issue.1 , pp. 88-94
    • Advani, R.H.1    Buggy, J.J.2    Sharman, J.P.3
  • 36
    • 84874585216 scopus 로고    scopus 로고
    • The bruton[U+05F3]s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the abc subtype of relapsed/refractory de novo diffuse large b-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study
    • Wilson W., Gerecitano J., Goy A., De Vos S. The bruton[U+05F3]s tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), has preferential activity in the abc subtype of relapsed/refractory de novo diffuse large b-cell lymphoma (DLBCL): interim results of a multicenter, open-label, phase 2 study. Blood 2012, 120(21):a686.
    • (2012) Blood , vol.120 , Issue.21 , pp. a686
    • Wilson, W.1    Gerecitano, J.2    Goy, A.3    De Vos, S.4
  • 37
    • 84904999787 scopus 로고    scopus 로고
    • Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study
    • Younes A., Thieblemont C., Morschhauser F., et al. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Lancet Oncol 2014, 15(9):1019-1026.
    • (2014) Lancet Oncol , vol.15 , Issue.9 , pp. 1019-1026
    • Younes, A.1    Thieblemont, C.2    Morschhauser, F.3
  • 38
    • 84925239641 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL)
    • (suppl; abstr TPS8615).
    • Younes A.Z.P., Sehn L.H., Johnson P.W., et al. A randomized, double-blind, placebo-controlled phase 3 study of ibrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in subjects with newly diagnosed nongerminal center B-cell subtype of diffuse large B-cell lymphoma (DLBCL). J Clin OncolJ Clin Oncol 2014, 32(5s). (suppl; abstr TPS8615).
    • (2014) J Clin OncolJ Clin Oncol , vol.32 , Issue.5 S
    • Younes, A.Z.P.1    Sehn, L.H.2    Johnson, P.W.3
  • 39
    • 34249075706 scopus 로고    scopus 로고
    • Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma
    • Robertson M.J., Kahl B.S., Vose J.M., et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007, 25(13):1741-1746.
    • (2007) J Clin Oncol , vol.25 , Issue.13 , pp. 1741-1746
    • Robertson, M.J.1    Kahl, B.S.2    Vose, J.M.3
  • 40
    • 84898401507 scopus 로고    scopus 로고
    • A phase III study of enzastaurin in patients with high-risk diffuse large B cell lymphoma following response to primary treatment: the Prelude trial
    • Crump M.L.S., Fayad L.E., Lee J., et al. A phase III study of enzastaurin in patients with high-risk diffuse large B cell lymphoma following response to primary treatment: the Prelude trial. Blood 2013, 122(21):a623.
    • (2013) Blood , vol.122 , Issue.21 , pp. a623
    • Crump, M.L.S.1    Fayad, L.E.2    Lee, J.3
  • 41
    • 84857640749 scopus 로고    scopus 로고
    • Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis
    • (abstr 8016).
    • Hainsworth JD AE, McCleod M., Fayad L., Hamid O., Davis L., Lin B.K. Randomized phase II study of R-CHOP plus enzastaurin versus R-CHOP in the first-line treatment of patients with intermediate- and high-risk diffuse large B-cell lymphoma (DLBCL): Preliminary analysis. J Clin OncolJ Clin Oncol 2011, 29(suppl). (abstr 8016).
    • (2011) J Clin OncolJ Clin Oncol , vol.29
    • Hainsworth, J.D.A.E.1    McCleod, M.2    Fayad, L.3    Hamid, O.4    Davis, L.5    Lin, B.K.6
  • 42
    • 79953323846 scopus 로고    scopus 로고
    • Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas
    • Naylor T.L., Tang H., Ratsch B.A., et al. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res 2011, 71(7):2643-2653.
    • (2011) Cancer Res , vol.71 , Issue.7 , pp. 2643-2653
    • Naylor, T.L.1    Tang, H.2    Ratsch, B.A.3
  • 43
    • 0034084163 scopus 로고    scopus 로고
    • Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity
    • Karin M., Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 2000, 18:621-663.
    • (2000) Annu Rev Immunol , vol.18 , pp. 621-663
    • Karin, M.1    Ben-Neriah, Y.2
  • 44
    • 84858113865 scopus 로고    scopus 로고
    • No one can whistle a symphony alone - how different ubiquitin linkages cooperate to orchestrate NF-kappaB activity
    • Schmukle A.C., Walczak H. No one can whistle a symphony alone - how different ubiquitin linkages cooperate to orchestrate NF-kappaB activity. J Cell Sci 2012, 125(Pt 3):549-559.
    • (2012) J Cell Sci , vol.125 , pp. 549-559
    • Schmukle, A.C.1    Walczak, H.2
  • 45
    • 84904283182 scopus 로고    scopus 로고
    • Bortezomib inhibits proteasomal degradation of IkappaBalpha and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma
    • Bu R., Hussain A.R., Al-Obaisi K.A., Ahmed M., Uddin S., Al-Kuraya K.S. Bortezomib inhibits proteasomal degradation of IkappaBalpha and induces mitochondrial dependent apoptosis in activated B-cell diffuse large B-cell lymphoma. Leuk Lymphoma 2014, 55(2):415-424.
    • (2014) Leuk Lymphoma , vol.55 , Issue.2 , pp. 415-424
    • Bu, R.1    Hussain, A.R.2    Al-Obaisi, K.A.3    Ahmed, M.4    Uddin, S.5    Al-Kuraya, K.S.6
  • 46
    • 19944428834 scopus 로고    scopus 로고
    • Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling
    • Lam L.T., Davis R.E., Pierce J., et al. Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling. Clin Cancer Res 2005, 11(1):28-40.
    • (2005) Clin Cancer Res , vol.11 , Issue.1 , pp. 28-40
    • Lam, L.T.1    Davis, R.E.2    Pierce, J.3
  • 47
    • 67650398258 scopus 로고    scopus 로고
    • Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma
    • Dunleavy K., Pittaluga S., Czuczman M.S., et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood 2009, 113(24):6069-6076.
    • (2009) Blood , vol.113 , Issue.24 , pp. 6069-6076
    • Dunleavy, K.1    Pittaluga, S.2    Czuczman, M.S.3
  • 48
    • 84889084747 scopus 로고    scopus 로고
    • Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study
    • Zinzani P.L., Pellegrini C., Merla E., et al. Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study. Hematol Oncol 2013, 31(4):179-182.
    • (2013) Hematol Oncol , vol.31 , Issue.4 , pp. 179-182
    • Zinzani, P.L.1    Pellegrini, C.2    Merla, E.3
  • 49
    • 79952154013 scopus 로고    scopus 로고
    • Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma
    • Ruan J., Martin P., Furman R.R., et al. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 2011, 29(6):690-697.
    • (2011) J Clin Oncol , vol.29 , Issue.6 , pp. 690-697
    • Ruan, J.1    Martin, P.2    Furman, R.R.3
  • 50
    • 77953937449 scopus 로고    scopus 로고
    • The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo
    • Dasmahapatra G., Lembersky D., Kramer L., et al. The pan-HDAC inhibitor vorinostat potentiates the activity of the proteasome inhibitor carfilzomib in human DLBCL cells in vitro and in vivo. Blood 2010, 115(22):4478-4487.
    • (2010) Blood , vol.115 , Issue.22 , pp. 4478-4487
    • Dasmahapatra, G.1    Lembersky, D.2    Kramer, L.3
  • 51
    • 84890992528 scopus 로고    scopus 로고
    • The irreversible proteasome inhibitor carfilzomib interacts synergistically with the selective HDAC6 inhibitor ACY1215 in ABC- and GC-DLBCL and mantle cell lymphoma sensitive or resistant to bortezomib
    • Dasmahapatra G.P.H., Al-Khafaji J.T., Fisher R.I., Friedberg J.W., Grant S. The irreversible proteasome inhibitor carfilzomib interacts synergistically with the selective HDAC6 inhibitor ACY1215 in ABC- and GC-DLBCL and mantle cell lymphoma sensitive or resistant to bortezomib. Blood 2012, 120(21):2765.
    • (2012) Blood , vol.120 , Issue.21 , pp. 2765
    • Dasmahapatra, G.P.H.1    Al-Khafaji, J.T.2    Fisher, R.I.3    Friedberg, J.W.4    Grant, S.5
  • 52
    • 84889004860 scopus 로고    scopus 로고
    • Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients
    • Zinzani P.L., Pellegrini C., Derenzini E., Argnani L., Pileri S. Long-term efficacy of the combination of lenalidomide and rituximab in elderly relapsed/refractory diffuse large B-cell lymphoma patients. Hematol Oncol 2013, 31(4):223-224.
    • (2013) Hematol Oncol , vol.31 , Issue.4 , pp. 223-224
    • Zinzani, P.L.1    Pellegrini, C.2    Derenzini, E.3    Argnani, L.4    Pileri, S.5
  • 53
    • 79959722615 scopus 로고    scopus 로고
    • An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin[U+05F3]s lymphoma
    • Witzig T.E., Vose J.M., Zinzani P.L., et al. An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin[U+05F3]s lymphoma. Ann Oncol 2011, 22(7):1622-1627.
    • (2011) Ann Oncol , vol.22 , Issue.7 , pp. 1622-1627
    • Witzig, T.E.1    Vose, J.M.2    Zinzani, P.L.3
  • 54
    • 54449095901 scopus 로고    scopus 로고
    • Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin[U+05F3]s lymphoma
    • Wiernik P.H., Lossos I.S., Tuscano J.M., et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin[U+05F3]s lymphoma. J Clin OncolJ Clin Oncol 2008, 26(30):4952-4957.
    • (2008) J Clin OncolJ Clin Oncol , vol.26 , Issue.30 , pp. 4952-4957
    • Wiernik, P.H.1    Lossos, I.S.2    Tuscano, J.M.3
  • 55
    • 84923922267 scopus 로고    scopus 로고
    • Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study
    • Nowakowski G.S., LaPlant B., Macon W.R., et al. Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study. J Clin OncolJ Clin Oncol Aug 18 2014.
    • (2014) J Clin OncolJ Clin Oncol
    • Nowakowski, G.S.1    LaPlant, B.2    Macon, W.R.3
  • 56
    • 84873571469 scopus 로고    scopus 로고
    • Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma
    • Tilly H., Morschhauser F., Salles G., et al. Phase 1b study of lenalidomide in combination with rituximab-CHOP (R2-CHOP) in patients with B-cell lymphoma. Leukemia 2013, 27(1):252-255.
    • (2013) Leukemia , vol.27 , Issue.1 , pp. 252-255
    • Tilly, H.1    Morschhauser, F.2    Salles, G.3
  • 57
    • 84901391325 scopus 로고    scopus 로고
    • Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial
    • Vitolo U., Chiappella A., Franceschetti S., et al. Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial. Lancet Oncol 2014, 15(7):730-737.
    • (2014) Lancet Oncol , vol.15 , Issue.7 , pp. 730-737
    • Vitolo, U.1    Chiappella, A.2    Franceschetti, S.3
  • 58
    • 79960220394 scopus 로고    scopus 로고
    • Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response
    • Lopez-Girona A., Heintel D., Zhang L.H., et al. Lenalidomide downregulates the cell survival factor, interferon regulatory factor-4, providing a potential mechanistic link for predicting response. Br J Haematol 2011, 154(3):325-336.
    • (2011) Br J Haematol , vol.154 , Issue.3 , pp. 325-336
    • Lopez-Girona, A.1    Heintel, D.2    Zhang, L.H.3
  • 59
    • 69949096727 scopus 로고    scopus 로고
    • Mechanism of action of lenalidomide in hematological malignancies
    • Kotla V., Goel S., Nischal S., et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2009, 2:36.
    • (2009) J Hematol Oncol , vol.2 , pp. 36
    • Kotla, V.1    Goel, S.2    Nischal, S.3
  • 60
    • 84873076585 scopus 로고    scopus 로고
    • Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression
    • Zhang L.H., Kosek J., Wang M., Heise C., Schafer P.H., Chopra R. Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression. Br J Haematol 2013, 160(4):487-502.
    • (2013) Br J Haematol , vol.160 , Issue.4 , pp. 487-502
    • Zhang, L.H.1    Kosek, J.2    Wang, M.3    Heise, C.4    Schafer, P.H.5    Chopra, R.6
  • 61
    • 84862152044 scopus 로고    scopus 로고
    • Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma
    • Yang Y., Shaffer A.L., Emre N.C., et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. Cancer Cell 2012, 21(6):723-737.
    • (2012) Cancer Cell , vol.21 , Issue.6 , pp. 723-737
    • Yang, Y.1    Shaffer, A.L.2    Emre, N.C.3
  • 62
    • 84881664038 scopus 로고    scopus 로고
    • Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation
    • Vose J.M., Habermann T.M., Czuczman M.S., et al. Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. Br J Haematol 2013, 162(5):639-647.
    • (2013) Br J Haematol , vol.162 , Issue.5 , pp. 639-647
    • Vose, J.M.1    Habermann, T.M.2    Czuczman, M.S.3
  • 63
    • 80053502780 scopus 로고    scopus 로고
    • Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype
    • Hernandez-Ilizaliturri F.J., Deeb G., Zinzani P.L., et al. Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer 2011, 117(22):5058-5066.
    • (2011) Cancer , vol.117 , Issue.22 , pp. 5058-5066
    • Hernandez-Ilizaliturri, F.J.1    Deeb, G.2    Zinzani, P.L.3
  • 64
    • 84887011781 scopus 로고    scopus 로고
    • Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi
    • Chiappella A., Tucci A., Castellino A., et al. Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. Haematologica 2013, 98(11):1732-1738.
    • (2013) Haematologica , vol.98 , Issue.11 , pp. 1732-1738
    • Chiappella, A.1    Tucci, A.2    Castellino, A.3
  • 65
    • 84874650275 scopus 로고    scopus 로고
    • Development of PI3K inhibitors: lessons learned from early clinical trials
    • Rodon J., Dienstmann R., Serra V., Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 2013, 10(3):143-153.
    • (2013) Nat Rev Clin Oncol , vol.10 , Issue.3 , pp. 143-153
    • Rodon, J.1    Dienstmann, R.2    Serra, V.3    Tabernero, J.4
  • 66
    • 51649111684 scopus 로고    scopus 로고
    • Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
    • Lenz G., Wright G.W., Emre N.C., et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci U S A 2008, 105(36):13520-13525.
    • (2008) Proc Natl Acad Sci U S A , vol.105 , Issue.36 , pp. 13520-13525
    • Lenz, G.1    Wright, G.W.2    Emre, N.C.3
  • 67
    • 84880672380 scopus 로고    scopus 로고
    • PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma
    • Pfeifer M., Grau M., Lenze D., et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A 2013, 110(30):12420-12425.
    • (2013) Proc Natl Acad Sci U S A , vol.110 , Issue.30 , pp. 12420-12425
    • Pfeifer, M.1    Grau, M.2    Lenze, D.3
  • 68
    • 79953655788 scopus 로고    scopus 로고
    • CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 delta, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia
    • Furman R.R., Byrd J.C., Brown J.R., et al. CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 delta, demonstrates clinical activity and pharmacodynamic effects in patients with relapsed or refractory chronic lymphocytic leukemia. Blood 2010, 116(21):31.
    • (2010) Blood , vol.116 , Issue.21 , pp. 31
    • Furman, R.R.1    Byrd, J.C.2    Brown, J.R.3
  • 69
    • 79958784935 scopus 로고    scopus 로고
    • Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 delta, in patients with relapsed or refractory non-Hodgkin lymphoma
    • Kahl B., Byrd J.C., Flinn I.W., et al. Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase P110 delta, in patients with relapsed or refractory non-Hodgkin lymphoma. Blood 2010, 116(21):741.
    • (2010) Blood , vol.116 , Issue.21 , pp. 741
    • Kahl, B.1    Byrd, J.C.2    Flinn, I.W.3
  • 70
    • 84893326301 scopus 로고    scopus 로고
    • Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-delta,gamma in patients with relapsed/refractory lymphoma
    • Horwitz S.M., Flinn I., Patel M.R., et al. Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-delta,gamma in patients with relapsed/refractory lymphoma. J Clin Oncol 2013, 31(15).
    • (2013) J Clin Oncol , vol.31 , Issue.15
    • Horwitz, S.M.1    Flinn, I.2    Patel, M.R.3
  • 71
    • 84906812169 scopus 로고    scopus 로고
    • Preliminary results of a phase II study of single agent bay 80-6946, a novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma
    • Dreyling M., Morschhauser F., Bron D., et al. Preliminary results of a phase II study of single agent bay 80-6946, a novel PI3K inhibitor, in patients with relapsed/refractory, indolent or aggressive lymphoma. Blood 2013, 122(21).
    • (2013) Blood , vol.122 , Issue.21
    • Dreyling, M.1    Morschhauser, F.2    Bron, D.3
  • 72
    • 79751526328 scopus 로고    scopus 로고
    • A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma
    • Witzig T.E., Reeder C.B., LaPlant B.R., et al. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011, 25(2):341-347.
    • (2011) Leukemia , vol.25 , Issue.2 , pp. 341-347
    • Witzig, T.E.1    Reeder, C.B.2    LaPlant, B.R.3
  • 73
    • 78149239933 scopus 로고    scopus 로고
    • Temsirolimus has activity in non-mantle cell non-Hodgkin[U+05F3]s lymphoma subtypes: The University of Chicago phase II consortium
    • Smith S.M., van Besien K., Karrison T., et al. Temsirolimus has activity in non-mantle cell non-Hodgkin[U+05F3]s lymphoma subtypes: The University of Chicago phase II consortium. J Clin Oncol 2010, 28(31):4740-4746.
    • (2010) J Clin Oncol , vol.28 , Issue.31 , pp. 4740-4746
    • Smith, S.M.1    van Besien, K.2    Karrison, T.3
  • 74
    • 84875651324 scopus 로고    scopus 로고
    • Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma
    • Barnes J.A., Jacobsen E., Feng Y., et al. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. Haematologica 2013, 98(4):615-619.
    • (2013) Haematologica , vol.98 , Issue.4 , pp. 615-619
    • Barnes, J.A.1    Jacobsen, E.2    Feng, Y.3
  • 75
    • 84902254046 scopus 로고    scopus 로고
    • The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients
    • Davids M.S., Seymour J.F., Gerecitano J.F., et al. The single-agent Bcl-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in all mantle cell lymphoma (MCL) patients. Blood 2013, 122:21.
    • (2013) Blood , vol.122 , pp. 21
    • Davids, M.S.1    Seymour, J.F.2    Gerecitano, J.F.3
  • 76
    • 84873540049 scopus 로고    scopus 로고
    • ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
    • Souers A.J., Leverson J.D., Boghaert E.R., et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013, 19(2):202-208.
    • (2013) Nat Med , vol.19 , Issue.2 , pp. 202-208
    • Souers, A.J.1    Leverson, J.D.2    Boghaert, E.R.3
  • 77
    • 84885421557 scopus 로고    scopus 로고
    • Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL)
    • Davids M.S., Seymour J.F., Gerecitano J.F., et al. Updated results of a phase I first-in-human study of the BCL-2 inhibitor ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL). J Clin Oncol 2013, 31:15.
    • (2013) J Clin Oncol , vol.31 , pp. 15
    • Davids, M.S.1    Seymour, J.F.2    Gerecitano, J.F.3
  • 78
    • 84910091007 scopus 로고    scopus 로고
    • Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses
    • (suppl; abstr 8522)
    • Davids M.S., Seymour J.F., Gerecitano J.F., et al. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. J Clin OncolJ Clin Oncol 2014, 32(5S). (suppl; abstr 8522).
    • (2014) J Clin OncolJ Clin Oncol , vol.32 , Issue.5 S
    • Davids, M.S.1    Seymour, J.F.2    Gerecitano, J.F.3
  • 79
    • 38949165127 scopus 로고    scopus 로고
    • Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas
    • Ding B.B., Yu J.J., Yu R.Y., et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008, 111(3):1515-1523.
    • (2008) Blood , vol.111 , Issue.3 , pp. 1515-1523
    • Ding, B.B.1    Yu, J.J.2    Yu, R.Y.3
  • 80
    • 79955485953 scopus 로고    scopus 로고
    • STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma
    • Scuto A., Kujawski M., Kowolik C., et al. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res 2011, 71(9):3182-3188.
    • (2011) Cancer Res , vol.71 , Issue.9 , pp. 3182-3188
    • Scuto, A.1    Kujawski, M.2    Kowolik, C.3
  • 81
    • 84869401524 scopus 로고    scopus 로고
    • Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes
    • Younes A., Romaguera J., Fanale M., et al. Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes. J Clin OncolJ Clin Oncol 2012, 30(33):4161-4167.
    • (2012) J Clin OncolJ Clin Oncol , vol.30 , Issue.33 , pp. 4161-4167
    • Younes, A.1    Romaguera, J.2    Fanale, M.3
  • 82
    • 84877815031 scopus 로고    scopus 로고
    • EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation
    • Beguelin W., Popovic R., Teater M., et al. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer Cell 2013, 23(5):677-692.
    • (2013) Cancer Cell , vol.23 , Issue.5 , pp. 677-692
    • Beguelin, W.1    Popovic, R.2    Teater, M.3
  • 83
    • 78650062951 scopus 로고    scopus 로고
    • EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis
    • Velichutina I., Shaknovich R., Geng H., et al. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood 2010, 116(24):5247-5255.
    • (2010) Blood , vol.116 , Issue.24 , pp. 5247-5255
    • Velichutina, I.1    Shaknovich, R.2    Geng, H.3
  • 84
    • 84871841675 scopus 로고    scopus 로고
    • Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation
    • Qi W., Chan H., Teng L., et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci U S A 2012, 109(52):21360-21365.
    • (2012) Proc Natl Acad Sci U S A , vol.109 , Issue.52 , pp. 21360-21365
    • Qi, W.1    Chan, H.2    Teng, L.3
  • 85
    • 84870573126 scopus 로고    scopus 로고
    • EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
    • McCabe M.T., Ott H.M., Ganji G., et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 2012, 492(7427):108-112.
    • (2012) Nature , vol.492 , Issue.7427 , pp. 108-112
    • McCabe, M.T.1    Ott, H.M.2    Ganji, G.3
  • 86
    • 80053651202 scopus 로고    scopus 로고
    • Targeting MYC dependence in cancer by inhibiting BET bromodomains
    • Mertz J.A., Conery A.R., Bryant B.M., et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci U S A 2011, 108(40):16669-16674.
    • (2011) Proc Natl Acad Sci U S A , vol.108 , Issue.40 , pp. 16669-16674
    • Mertz, J.A.1    Conery, A.R.2    Bryant, B.M.3
  • 87
    • 80052955256 scopus 로고    scopus 로고
    • BET bromodomain inhibition as a therapeutic strategy to target c-Myc
    • Delmore J.E., Issa G.C., Lemieux M.E., et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011, 146(6):904-917.
    • (2011) Cell , vol.146 , Issue.6 , pp. 904-917
    • Delmore, J.E.1    Issa, G.C.2    Lemieux, M.E.3
  • 88
    • 84942516634 scopus 로고    scopus 로고
    • BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies
    • Herait P., Berthon C., Thieblemont C., et al. BET-bromodomain inhibitor OTX015 shows clinically meaningful activity at nontoxic doses: interim results of an ongoing phase I trial in hematologic malignancies. Am Assoc Cancer Res 2014.
    • (2014) Am Assoc Cancer Res
    • Herait, P.1    Berthon, C.2    Thieblemont, C.3
  • 89
    • 84879866976 scopus 로고    scopus 로고
    • PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies
    • Chen B.J., Chapuy B., Ouyang J., et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013, 19(13):3462-3473.
    • (2013) Clin Cancer Res , vol.19 , Issue.13 , pp. 3462-3473
    • Chen, B.J.1    Chapuy, B.2    Ouyang, J.3
  • 90
    • 84890096527 scopus 로고    scopus 로고
    • Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial
    • Armand P., Nagler A., Weller E.A., et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 2013, 31(33):4199206.
    • (2013) J Clin Oncol , vol.31 , Issue.33 , pp. 4199206
    • Armand, P.1    Nagler, A.2    Weller, E.A.3
  • 91
    • 84907293786 scopus 로고    scopus 로고
    • Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor
    • Kochenderfer J.N., Dudley M.E., Kassim S.H., et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2014.
    • (2014) J Clin Oncol
    • Kochenderfer, J.N.1    Dudley, M.E.2    Kassim, S.H.3
  • 92
    • 84963534762 scopus 로고    scopus 로고
    • Effective treatment of chemotherapy-refractory diffuse large B-cell lymphoma with autologous t cells genetically-engineered to express an anti-CD19 chimeric antigen receptor
    • Kochenderfer J.N., Dudley M.E., Kassim S.H., et al. Effective treatment of chemotherapy-refractory diffuse large B-cell lymphoma with autologous t cells genetically-engineered to express an anti-CD19 chimeric antigen receptor. Blood 2013, 122:21.
    • (2013) Blood , vol.122 , pp. 21
    • Kochenderfer, J.N.1    Dudley, M.E.2    Kassim, S.H.3
  • 93
    • 84910006341 scopus 로고    scopus 로고
    • Precision therapy for lymphoma-current state and future directions
    • Intlekofer A.M., Younes A. Precision therapy for lymphoma-current state and future directions. Nat Rev Clin Oncol 2014.
    • (2014) Nat Rev Clin Oncol
    • Intlekofer, A.M.1    Younes, A.2
  • 94
    • 84899448200 scopus 로고    scopus 로고
    • Diffuse large B-cell lymphoma: changing treatment paradigms
    • Batlevi C.L., Younes A. Diffuse large B-cell lymphoma: changing treatment paradigms. Oncology 2014, 28(4):339-341.
    • (2014) Oncology , vol.28 , Issue.4 , pp. 339-341
    • Batlevi, C.L.1    Younes, A.2
  • 95
    • 41149136296 scopus 로고    scopus 로고
    • Oncogenic CARD11 mutations in human diffuse large B cell lymphoma
    • Lenz G., Davis R.E., Ngo V.N., et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science 2008, 319(5870):1676-1679.
    • (2008) Science , vol.319 , Issue.5870 , pp. 1676-1679
    • Lenz, G.1    Davis, R.E.2    Ngo, V.N.3
  • 96
    • 0026722655 scopus 로고
    • Cooperative interaction between c-myc and bcl-2 proto-oncogenes
    • Fanidi A., Harrington E.A., Evan G.I. Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 1992, 359(6395):554-556.
    • (1992) Nature , vol.359 , Issue.6395 , pp. 554-556
    • Fanidi, A.1    Harrington, E.A.2    Evan, G.I.3
  • 97
    • 0026688162 scopus 로고
    • Apoptotic cell death induced by c-myc is inhibited by bcl-2
    • Bissonnette R.P., Echeverri F., Mahboubi A., Green D.R. Apoptotic cell death induced by c-myc is inhibited by bcl-2. Nature 1992, 359(6395):552-554.
    • (1992) Nature , vol.359 , Issue.6395 , pp. 552-554
    • Bissonnette, R.P.1    Echeverri, F.2    Mahboubi, A.3    Green, D.R.4
  • 98
    • 84877929526 scopus 로고    scopus 로고
    • ABT-199 a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia
    • Vandenberg C.J., Cory S. ABT-199 a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 2013, 121(12):2285-2288.
    • (2013) Blood , vol.121 , Issue.12 , pp. 2285-2288
    • Vandenberg, C.J.1    Cory, S.2
  • 99
    • 84865114403 scopus 로고    scopus 로고
    • Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis
    • Sander S., Calado D.P., Srinivasan L., et al. Synergy between PI3K signaling and MYC in Burkitt lymphomagenesis. Cancer Cell 2012, 22(2):167-179.
    • (2012) Cancer Cell , vol.22 , Issue.2 , pp. 167-179
    • Sander, S.1    Calado, D.P.2    Srinivasan, L.3
  • 100
    • 77951566551 scopus 로고    scopus 로고
    • NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma
    • Han S.S., Yun H., Son D.J., et al. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. Molec Cancer 2010, 9:97.
    • (2010) Molec Cancer , vol.9 , pp. 97
    • Han, S.S.1    Yun, H.2    Son, D.J.3
  • 101
    • 84879437606 scopus 로고    scopus 로고
    • Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas
    • Shortt J., Martin B.P., Newbold A., et al. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood 2013, 121(15):2964-2974.
    • (2013) Blood , vol.121 , Issue.15 , pp. 2964-2974
    • Shortt, J.1    Martin, B.P.2    Newbold, A.3
  • 102
    • 79960341257 scopus 로고    scopus 로고
    • Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin[U+05F3]s lymphoma
    • Civallero M., Cosenza M., Bari A., Sacchi S. Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin[U+05F3]s lymphoma. Expert Opin Inv Drug 2011, 20(8):1029-1031.
    • (2011) Expert Opin Inv Drug , vol.20 , Issue.8 , pp. 1029-1031
    • Civallero, M.1    Cosenza, M.2    Bari, A.3    Sacchi, S.4
  • 103
    • 84871573163 scopus 로고    scopus 로고
    • Combination of NVP-BEZ235 and enzastaurin on B-cell lymphoma cell lines: an effective therapeutic strategy
    • Civallero M., Cosenza M., Pozzi S., Sacchi S. Combination of NVP-BEZ235 and enzastaurin on B-cell lymphoma cell lines: an effective therapeutic strategy. Blood 2011, 118(21):1170.
    • (2011) Blood , vol.118 , Issue.21 , pp. 1170
    • Civallero, M.1    Cosenza, M.2    Pozzi, S.3    Sacchi, S.4
  • 104
    • 84862727403 scopus 로고    scopus 로고
    • Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo
    • Dasmahapatra G., Lembersky D., Son M.P., et al. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo. Mol Cancer Ther 2012, 11(5):1122-1132.
    • (2012) Mol Cancer Ther , vol.11 , Issue.5 , pp. 1122-1132
    • Dasmahapatra, G.1    Lembersky, D.2    Son, M.P.3
  • 105
    • 84905641032 scopus 로고    scopus 로고
    • Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors
    • Ceribelli M., Kelly P.N., Shaffer A.L., et al. Blockade of oncogenic IkappaB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors. Proc Natl Acad Sci U S A 2014, 111(31):11365-11370.
    • (2014) Proc Natl Acad Sci U S A , vol.111 , Issue.31 , pp. 11365-11370
    • Ceribelli, M.1    Kelly, P.N.2    Shaffer, A.L.3
  • 106
    • 84893825160 scopus 로고    scopus 로고
    • High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells
    • Mathews Griner L.A., Guha R., Shinn P., et al. High-throughput combinatorial screening identifies drugs that cooperate with ibrutinib to kill activated B-cell-like diffuse large B-cell lymphoma cells. Proc Natl Acad Sci U S A 2014, 111(6):2349-2354.
    • (2014) Proc Natl Acad Sci U S A , vol.111 , Issue.6 , pp. 2349-2354
    • Mathews Griner, L.A.1    Guha, R.2    Shinn, P.3
  • 107
    • 84890606231 scopus 로고    scopus 로고
    • Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma
    • Oki Y., Buglio D., Fanale M., et al. Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma. Clin Cancer Res 2013, 19(24):6882-6890.
    • (2013) Clin Cancer Res , vol.19 , Issue.24 , pp. 6882-6890
    • Oki, Y.1    Buglio, D.2    Fanale, M.3
  • 108
    • 84859770736 scopus 로고    scopus 로고
    • Phase 1 trial of sorafenib and everolimus in patients with lymphoma or multiple myeloma
    • Kumar S., Porrata L.F., Ansell S.M., et al. Phase 1 trial of sorafenib and everolimus in patients with lymphoma or multiple myeloma. Blood 2010, 116(21):1155-1156.
    • (2010) Blood , vol.116 , Issue.21 , pp. 1155-1156
    • Kumar, S.1    Porrata, L.F.2    Ansell, S.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.